AI illustration · not actual product photoDetails from the source.
This catalogue entry records Hexarelin, 5 mg × 10 vials (SKU HX5), using the supplied source listing. The cited dossier describes: Research has examined growth-hormone secretion and acute cardiovascular physiology. Animal and in-vitro work has explored cardiac function, ischemia-related injury, fibrosis, and cell effects. These research topics should not be represented as proven treatment effects. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- HX5
- Source specification
- 5mg*10vials
- Source document
- PriceList(1).pdf, page 3
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
Hexarelin as described in scientific literature is a synthetic six-amino-acid peptide and growth-hormone secretagogue. Preserve the exact catalogue label ‘Hexarelin Acetate.’ The supplied catalogue does not verify the content, salt form, manufacturer, purity, sterility, or regulatory category of the HX5 vial. Do not label this exact item compounded or research-only without supporting documentation.
Biological mechanism
Hexarelin activates GHSR1a, the ghrelin receptor, and stimulates growth-hormone release. Small human studies also report acute changes in prolactin and cortisol; some overnight research reports ACTH changes. Separate cardiac studies propose GHSR1a- and CD36-related effects, much of which remains cell, isolated-tissue, or animal evidence rather than established human benefit. [1] [2] [3]
Research focus
Research has examined growth-hormone secretion and acute cardiovascular physiology. Animal and in-vitro work has explored cardiac function, ischemia-related injury, fibrosis, and cell effects. These research topics should not be represented as proven treatment effects. [1] [3]
Potential applications in the evidence
Investigated in controlled research as a stimulus of growth-hormone release and in acute studies of cardiac physiology. These findings do not establish an approved or effective treatment use, including for growth-hormone deficiency or cardiovascular disease. Animal and in-vitro findings must remain distinct from human observations. [1] [3]
Human evidence
Small, short-term human studies show acute growth-hormone release. A dose-response clinical trial in healthy adult men also observed prolactin and cortisol increases. A small overnight study reported changes in GH, ACTH, cortisol, and prolactin and reduced slow-wave sleep. In an acute controlled study of 24 men undergoing coronary bypass surgery, hexarelin changed measured cardiac performance and hemodynamic variables. These studies establish short-term physiological responses in their specific settings, not durable benefit, long-term safety, or disease-treatment efficacy. [1] [2] [3]
Known and potential effects
Reported human pharmacologic effects include acute increases in GH, prolactin, and cortisol, with ACTH changes in an overnight study; that small sleep study also reported reduced slow-wave sleep. These are observed responses and do not constitute a complete adverse-event profile. A CD36-related increase in coronary perfusion pressure has been reported in isolated-heart experiments; this is preclinical, not a demonstrated clinical adverse event. [1] [2] [3]
Safety and contraindications
Available studies are too small and brief to establish the frequency or severity of harms, long-term endocrine or cardiovascular effects, interactions, or a complete contraindication list. The effects on multiple hormone signals and the preclinical cardiac findings merit caution in interpreting safety, but do not support an invented contraindication list. Risk for this specific vial cannot be assessed without verified identity, composition, excipients, sterility, manufacturing, and lot-quality information. No use or administration advice is provided. [1] [2] [3]
U.S. FDA / regulatory status
As of 2026-10-30, no FDA-approved hexarelin active ingredient or branded formulation was identified in the FDA approval resources searched; this is not a determination about every jurisdiction or this supplier-specific vial. FDA states that NDC-directory entries can include approved and unapproved products and that listing is not FDA approval or verification. A 2025 FDA warning letter discusses a separate firm’s ‘Hexarelin Acetate’ listing and a discrepancy between the ingredient name and its structured product labeling; this does not establish anything about HX5. The source gives no manufacturer, lot, formulation source, jurisdiction, approval identifier, product label, or certificate of analysis, so exact-vial identity and approval status cannot be verified. Do not transfer any other product’s approval to HX5. [4] [5] [6]
Evidence limitations
Human evidence is limited, old, and largely acute, involving small and selected groups; longer-term outcomes and broad safety are not established. Much of the proposed cardiac/tissue activity comes from animals, isolated tissues, or cells, not clinical efficacy trials. Findings about hexarelin as a molecule do not authenticate the source-specific HX5 vial or prove its label reflects its contents. The catalogue lists HX5 as Hexarelin Acetate, *10vials, price 81 per 10 vials; it does not state the currency. [1] [2] [3] [6]
Supporting sources
- Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study The Journal of Clinical Endocrinology & Metabolism / PubMed (NLM) · Primary human clinical trial; PubMed record. Supports: Acute dose-response GH, prolactin, and cortisol findings in healthy adult men; human pharmacologic effects and evidence limitations.
- The Safety and Efficacy of Growth Hormone Secretagogues Sexual Medicine Reviews / PubMed Central (NLM) · Peer-reviewed review. Supports: Human overnight hexarelin study findings on GH, ACTH, cortisol, prolactin, and slow-wave sleep; supports limited human safety evidence.
- The cardiovascular action of hexarelin Journal of Geriatric Cardiology / PubMed Central (NLM) · Peer-reviewed review. Supports: Hexarelin peptide identity, GHSR1a and CD36 mechanisms, acute human cardiac research, and distinction between clinical observations and preclinical evidence.
- Drug Approvals and Databases U.S. Food and Drug Administration · Official regulator database portal. Supports: FDA approval-resource context for checking approved drug products; does not establish approval of this catalogue vial.
- National Drug Code Directory U.S. Food and Drug Administration · Official regulator database and policy information. Supports: FDA statement that NDC listing is not FDA verification or approval and that the directory includes approved and unapproved listings.
- Darmerica, LLC - 716152 - 12/08/2025 U.S. Food and Drug Administration · Official FDA warning letter. Supports: FDA’s discussion of a distinct company’s Hexarelin Acetate listing with a labeling/active-ingredient discrepancy; explicitly not evidence about HX5.